Qualitative and quantitative assessment of relative agonist efficacy

Biochemical Pharmacology

Volumn 58, Issue 5, 1999, Pages 735-748

  Christopoulos, Arthur ^a   El Fakahany, Esam E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Affinity; Agonism; Concentration response analysis; Intrinsic efficacy; Radioligand binding; Receptor theory

Indexed keywords

ACETYLCHOLINE; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR; PARTIAL AGONIST; PILOCARPINE; RADIOLIGAND;

AGONIST; ANIMAL CELL; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; REVIEW; THEORY;

ANIMALS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC ENGINEERING; HUMANS; MODELS, BIOLOGICAL; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE;

EID: 0032777107     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00087-8     Document Type: Review

References (77)

1. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction. 1997;Lippincott-Raven, Philadelphia.
2. Clarke W.P., Bond R.A. The elusive nature of intrinsic efficacy. Trends Pharmacol Sci. 19:1998;270-276.
3. Clark A.J. General Pharmacology. 1937;Springer, Berlin.
4. Ariëns E.J. Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther. 99:1954;32-49.
5. Stephenson R.P. A modification of receptor theory. Br J Pharmacol. 11:1956;379-393.
6. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res. 3:1966;21-55.
7. Katz B., Thesleff S. A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J Physiol (Lond). 138:1957;63-80.
8. Frauenfelder H., Sligar S.G., Wolynes P.G. The energy landscapes and motions of proteins. Science. 254:1991;1598-1603.
9. Cuatrecasas P. Membrane receptors. Annu Rev Biochem. 43:1974;169-214.
10. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem. 255:1980;7108-7117.
11. 3H]bradykinin dissociates slowly. J Biol Chem. 265:1990;9621-9627.
12. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 268:1993;4625-4636.
13. Weiss J.M., Morgan P.H., Lutz M.W., Kenakin T.P. The cubic ternary complex receptor-occupancy model I. Model description. J Theor Biol. 178:1996;151-167.
14. Spedding M., Dacquet C. Transduction is a major factor influencing receptor characterization. Ann NY Acad Sci. 812:1997;29-40.
15. Kenakin T., Morgan P., Lutz M. On the importance of the "antagonist assumption" to how receptors express themselves. Biochem Pharmacol. 50:1995;17-26.
16. Kenakin TP, Molecular Pharmacology. A Short Course. Blackwell Science, Cambridge, MA, 1997.
17. Lefkowitz R.J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci. 14:1993;303-307.
18. Kenakin T.P. Challenges for receptor theory as a tool for drug and drug receptor classification. Trends Pharmacol Sci. 10:1989;18-22.
19. Nickerson M. Receptor occupancy and tissue response. Nature. 178:1956;697-698.
20. Jenkinson D.H. Classic approaches to the study of drug-receptor interactions. Foreman J.C., Johansen T. Textbook of Receptor Pharmacology. 1996;3-62 CRC Press, Boca Raton.
21. Lew M.J. Extended concentration-response curves used to reflect full agonist efficacies and receptor occupancy-response coupling ranges. Br J Pharmacol. 115:1995;745-752.
22. Szabadi E. A model of two functionally antagonistic receptor populations activated by the same agonist. J Theor Biol. 69:1977;101-112.
23. Rovati G.E., Nicosia S. Lower efficacy Interaction with an inhibitory receptor or partial agonism? Trends Pharmacol Sci. 15:1994;140-144.
24. Pliska V. Models to explain dose-response relationships that exhibit a downturn phase. Trends Pharmacol Sci. 15:1994;178-181.
25. Kenakin T.P. The quantification of relative efficacy of agonists. J Pharmacol Methods. 13:1985;281-308.
26. Mackay D. A general analysis of the receptor-drug interaction. Br J Pharmacol. 26:1966;9-16.
27. Furchgott R., Bursztyn P. Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci. 144:1967;882-899.
28. Black J.W., Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B. 220:1983;141-162.
29. Black J.W., Leff P., Shankley N.P., Wood J. An operational model of pharmacological agonism The effect of E/[A] curve shape on agonist dissociation constant estimation . Br J Pharmacol. 84:1985;561-571.
30. Barlow R.B., Scott N.C., Stephenson R.P. The affinity and efficacy of onium salts on the frog rectus abdominis. Br J Pharmacol. 31:1967;188-196.
31. Leff P., Prentice D.J., Giles H., Martin G.R., Wood J. Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods. 23:1990;225-237.
32. Waud D.R. On the measurement of the affinity of partial agonists for receptors. J Pharmacol Exp Ther. 170:1969;117-122.
33. Freeman K.A., Tallarida R.J. Determination of the functional dissociation constant of a partial agonist by comparison with a higher efficacy agonist. J Pharmacol Methods. 25:1991;11-18.
34. Limbird L.E. Cell Surface Receptors A Short Course on Theory and Methods . 1996;Kluwer Academic Publishers, Boston.
35. Colquhoun D. Affinity, efficacy, and receptor classification Is the classic theory still useful? Black J.W., Jenkinson D.H., Gerskowitch V.P. Perspectives on Receptor Classification. 1987;103-114 Alan R. Liss, New York.
36. Leff P., Dougall I.G., Harper D.H., Dainty I.A. Errors in agonist affinity estimation Do they and should they occur in isolated tissue experiments? Trends Pharmacol Sci. 11:1990;64-67.
37. Hulme E.C., Birdsall N.J.M. Strategy and tactics in receptor-binding studies. Hulme E.C. Receptor-Ligand Interactions. A Practical Approach. 1992;63-176 Oxford University Press, New York.
38. Birdsall N.J.M., Lazareno S. To what extent can binding studies allow the quantification of affinity and efficacy? Ann NY Acad Sci. 812:1997;41-47.
39. Chidiac P. Rethinking receptor-G protein-effector interactions. Biochem Pharmacol. 55:1998;549-556.
40. act? J Theor Biol. 187:1997;15-37.
41. Van Giersbergen P.L.M., Leppik R. Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors. Naunyn Schmiedebergs Arch Pharmacol. 352:1995;166-172.
42. Ehlert F.J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol. 28:1985;410-421.
43. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev. 48:1996;413-463.
44. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci. 18:1997;456-464.
45. Burgen A.S.V. Conformational changes and drug action. Fedn Proc. 40:1981;2723-2728.
46. Lameh J., Cone R.I., Maeda S., Philip M., Corbani M., Nádasdi L., Ramachandran J., Smith G.M., Sadée W. Structure and function of G protein coupled receptors. Pharm Res. 7:1990;1213-1221.
47. Savarese T.M., Fraser C.M. In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem J. 283:1992;1-19.
48. Strader C.D., Fong T.M., Tota M.R., Underwood D. Structure and function of G protein-coupled receptors. Annu Rev Biochem. 63:1994;101-132.
49. Scheer A., Cotecchia S. Constitutively active G protein-coupled receptors Potential mechanisms of receptor activation . J Recept Signal Transduct Res. 17:1997;57-73.
50. q. FEBS Lett. 363:1995;261-263.
51. 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA. 87:1990;2896-2900.
52. 1B-adrenergic receptor by all amino acid substitutions at a single site. J Biol Chem. 267:1992;1430-1433.
53. Kenakin T. Agonist-receptor efficacy. II Agonist trafficking of receptor signals . Trends Pharmacol Sci. 16:1995;232-238.
54. Kenakin T. Agonist-receptor efficacy. I Mechanisms of efficacy and receptor promiscuity . Trends Pharmacol Sci. 16:1995;188-192.
55. Perez D.M., Hwa J., Gaivin R., Mathur M., Brown F., Graham R.M. Constitutive activation of a single effector pathway Evidence for multiple activation states of a G protein-coupled receptor . Mol Pharmacol. 49:1996;112-122.
56. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors Evidence for agonist-directed trafficking of receptor stimulus . Mol Pharmacol. 54:1998;94-104.
57. Kenakin T. Agonist-specific receptor conformations. Trends Pharmacol Sci. 18:1997;416-417.
58. Costa T., Herz A. Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA. 86:1989;7321-7325.
59. Costa T., Ogino Y., Munson P.J., Onaran H.O., Rodbard D. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand . Mol Pharmacol. 41:1992;549-560.
60. 3H]-S15535 Definition of its binding profile using agonists, antagonists and inverse agonists . Naunyn Schmiedebergs Arch Pharmacol. 357:1998;205-217.
61. Bürgisser E., De Lean A., Lefkowitz R.J. Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc Natl Acad Sci USA. 79:1982;1732-1736.
62. 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem. 270:1995;28268-28275.
63. Gether U., Ballesteros J.A., Seifer R., Sanders-Bush E., Weinstein H., Kobilka B.K. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem. 272:1997;2587-2590.
64. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta. 1179:1993;171-188.
65. Su Y.-F., Harden T.K., Perkins J.P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J Biol Chem. 255:1980;7410-7419.
66. Hu J., Wang S.-Z., El-Fakahany E.E. Effects of agonist efficacy on desensitization of phosphoinositide hydrolysis mediated by m1 and m3 muscarinic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 257:1991;938-945.
67. Whaley B., Yuan N., Birnbaumer L., Clark R.B., Barber R. Differential expression of the β-adrenergic receptor modifies agonist stimulation of adenylyl cyclase A quantitative evaluation . Mol Pharmacol. 45:1994;481-489.
68. 2-Adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem. 272:1997;23871-23879.
69. Benovic J.L., Staniszewski C., Mayor F. Jr, Caron M.G., Lefkowitz R.J. β-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J Biol Chem. 263:1988;3893-3897.
70. 2-adrenergic receptor during agonist-induced steady-state redistribution. Mol Pharmacol. 50:1996;692-699.
71. Szekeres P.G., Koenig J.A., Edwardson J.M. The relationship between agonist intrinsic activity and the rate of endocytosis of muscarinic receptors in a human neuroblastoma cell line. Mol Pharmacol. 53:1998;759-765.
72. Stoll L., Muller W.E. In vitro down-regulation predicts agonist efficacy at central muscarinic cholinergic receptors. Biochem Pharmacol. 41:1991;1963-1966.
73. 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci USA. 91:1994;2699-2702.
74. 2-adrenergic receptor. Mol Pharmacol. 45:1994;390-394.
75. Westphal R.S., Backstrom J.R., Sanders-Bush E. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol Pharmacol. 48:1995;200-205.
76. Chidiac P., Hebert T.E., Valiquette M., Dennis M., Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol. 45:1994;490-499.
77. Onaran H.O., Costa T. Agonist efficacy and allosteric models of receptor activation. Ann NY Acad Sci. 812:1997;98-115.